Patents Examined by Myron G. Hill
  • Patent number: 11028151
    Abstract: Amino acid sequences are provided that are directed against/and or that can specifically bind protein F of hRSV, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, polypeptides and therapeutic compounds and compositions provided by the invention show an improved stability, less immunogenicity and/or improved affinity and/or avidity for protein F of hRSV. The invention also relates to the uses of such amino acid sequences, polypeptides, compounds or constructs for prophylactic and/or therapeutic purposes.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: June 8, 2021
    Assignee: Ablynx N.V.
    Inventors: Erik Depla, Catelijne Stortelers, Stephanie Staelens
  • Patent number: 11021520
    Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode an RSV immunogen are disclosed. Nucleic acids are disclosed that comprise the sequences that encodes consensus RSV F protein or immuno-genic fragment thereof, sequences that encodes an RSV G(A) protein or immunogenic fragment thereof and sequences that encodes an RSV G(B) protein or immunogenic fragment thereof. Compositions comprising one, combinations of two or all three sequences are disclosed. The coding sequences optionally include operable linked coding sequence that encode a signal peptide. Nucleic acid molecules and compositions comprising the chemokine CC20 and/or a consensus RSV M2-1 protein or immunogenic fragment thereof are also disclosed. Immunomodulatory methods and methods of inducing an immune response against RSV are disclosed. Methods of preventing RSV infection and methods of treating individuals infected with RSV are disclosed.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: June 1, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: David B. Weiner, Daniel Choo, Kar Muthumani, Nyamekye Obeng-Adjei, Veronica Scott
  • Patent number: 11020475
    Abstract: Disclosed is cold-adapted live attenuated severe acute respiratory syndrome coronavirus (SARS-CoV-2) prepared by infecting cells with severe acute respiratory syndrome coronavirus and then adapting the severe acute respiratory syndrome coronavirus to a temperature from 37° C. to 22° C. in a step by step manner. Further, a vaccine containing the cold-adapted live attenuated severe acute respiratory syndrome coronavirus (SARS-CoV-2) is disclosed.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: June 1, 2021
    Assignee: The Industry & Academic Cooperation in Chungnam National University (IAC)
    Inventors: Sang-Heui Seo, Yun-Yueng Jang
  • Patent number: 11021531
    Abstract: This disclosure provides antibodies and antigen-binding fragments that are derived from 2ghw and that can be administered to an individual that is infected or suspected of being infected with a virus. Antibodies and antigen-binding fragments provided herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to several weeks. Antibodies and antigen-binding fragments provided herein can be used to diagnose a SARS-Cov-2 infection.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: June 1, 2021
    Assignee: Centivax, Inc.
    Inventors: Jacob Glanville, Shahrad Daraeikia, I-Chieh Wang, Sindy Andrea Liao-Chan, Jean-Philippe Bürckert, Sawsan Youssef
  • Patent number: 11021532
    Abstract: This disclosure provides superhuman antibodies and antigen-binding fragments that can be administered to an individual that is infected or suspected of being infected with a virus. Superhuman antibodies and antigen-binding fragments provided herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to at least several weeks. Superhuman antibodies and antigen-binding fragments provided herein can be used to diagnose a SARS Cov-2 infection.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: June 1, 2021
    Assignee: Centivax, Inc.
    Inventors: Jacob Glanville, Shahrad Daraeikia, I-Chieh Wang, Sindy Andrea Liao-Chan
  • Patent number: 11015179
    Abstract: The present specification relates to an anti-viral composition and, more particularly, to a composition that both is anti-viral and prevents and treats diseases associated with viruses, containing a peptide derived from a telomerase, thereby being effective in treating and preventing diseases associated with viruses and pathological symptoms caused by viruses. The peptide exhibits an effect of treating diseases associated with viruses by inhibiting the RNA replication of viruses, thereby being capable of providing a method that both is antiviral and prevents and treats diseases associated with viruses.
    Type: Grant
    Filed: July 4, 2016
    Date of Patent: May 25, 2021
    Assignee: GemVax & KAEL Co., Ltd.
    Inventor: Sang Jae Kim
  • Patent number: 10983125
    Abstract: Provided are a marker for detecting a highly pathogenic influenza virus including a protein mutant prepared by substituting the amino acids 68 and 69 of a PB1-F2 protein, a composition for detecting a highly pathogenic virus including an agent for measuring the protein mutant, and a detection kit including the same, a method for detecting a highly pathogenic virus including measuring the protein mutant, an antiviral composition against influenza A virus including an inhibitor of binding between a PB1-F2 protein in which the amino acids 68 and 69 are substituted and DDX3, and a method for screening an antiviral substance against influenza A virus.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: April 20, 2021
    Assignee: Dandi Bioscience Inc
    Inventors: Kyun-Hwan Kim, Eun Sook Park, Yeong-Min Park, Baik Lin Seong, Young Ho Byun, Hye Min Lee
  • Patent number: 10980873
    Abstract: The invention relates to a genetically modified infectious measles virus derived from a live-attenuated measles virus strain, in which the gene encoding the viral accessory C protein has been knocked out (MV-deltaC). It concerns in particular the use of said genetically modified infectious MV-deltaC in the treatment of malignant tumour or cancer conditions, and for the preparation of agents or compositions for such treatment.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: April 20, 2021
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE NANTES
    Inventors: Frédéric Tangy, Marc Gregoire, Jean-François Fonteneau, Jean-Baptiste Guillerme, Chantal Combredet
  • Patent number: 10982221
    Abstract: The present invention describes the plant-based production of a therapeutic anti-virus antibody.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: April 20, 2021
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Qiang Chen, Huafang Lai, Jonathan Hurtado
  • Patent number: 10973899
    Abstract: The invention provides, inter alia, improved replicons and vectors encoding them, where the replicons provide sustained expression of an encoded protein. These replicons comprise flavivirus replicases and heterologous protein coding sequences, wherein the heterologous protein coding sequences are flanked by separation sequences for improved efficacy. These nucleic acids provided by the invention, including self-replicating RNAs provided by the invention, are useful in methods of protein expression, such as for vaccines (e.g., for methods of immunization), as well as expression of therapeutic proteins, such as antibodies (e.g., for methods of treatment).
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: April 13, 2021
    Assignee: Novartis AG
    Inventors: Caitlin Jeanette Hagen, Dong Yu, Peter W. Mason, Peter Shahinian
  • Patent number: 10967014
    Abstract: The invention relates to pneumoviral virions comprising a viral genome that has a mutation in a gene coding for a protein that is essential for infectivity of the pneumovirus, whereby the mutation causes a virus produced from only the viral genome to lack infectivity, and whereby the virion comprises the protein in a form and in an amount that is required for infectivity of the virion. The invention also relates to methods for producing the pneumoviral virions and for using the virions in the treatment or prevention of pneumoviral infection and disease. A preferred pneumoviral virion is a virion of Respiratory Syncytial Virus in which preferably the gene for the G attachment protein is inactivated and complemented in trans.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: April 6, 2021
    Assignee: De Staat der Nederlanden, vert. door de minister van VWS
    Inventors: Willem Luytjes, Myra Noorely Widjojoatmodjo
  • Patent number: 10899800
    Abstract: Described are stable pre-fusion respiratory syncitial virus (RSV) F polypeptides, immunogenic compositions comprising the polypeptides and uses thereof for the prevention and/or treatment of RSV infection.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: January 26, 2021
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Johannes Petrus Maria Langedijk, Anders Krarup
  • Patent number: 10894991
    Abstract: Disclosed herein is a method for validation of continuous viral clearance comprising the steps of providing a probe to be validated, spiking the probe in a valid manner, performing viral clearance, sampling the spiked probe and analyzing the sample of the spiked probe of step d).
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: January 19, 2021
    Assignee: BAYER AKTIENGESELLSCHAFT
    Inventors: Benjamin Maiser, Peter Schwan, Laura David, Martin Lobedann
  • Patent number: 10889797
    Abstract: Methods of purifying a virus from a virus-infected cell lysate using three-phase partitioning (TPP) are disclosed. The methods comprise a first round of TPP, including mixing a cell lysate comprising a virus with ammonium sulfate and t-butanol, and separating the mixture, thereby forming a first aqueous phase, a first organic phase, and a first interphase. The first aqueous phase can comprise the virus, which can be subjected to a second round of TPP, resulting in a second aqueous phase, a second organic phase, and a second interphase. The second interphase can comprise highly purified virus. The methods can comprise subjecting a first aqueous phase to further purification by column chromatography or density gradient centrifugation. Purification of AAV, including AAV2, AAV5 and AAV6, from lysates of infected insect cell cultures is demonstrated. TPP-purified AAV particles infect at least as well as those prepared by standard methods.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: January 12, 2021
    Assignee: Virovek Incorporation
    Inventor: Haifeng Chen
  • Patent number: 10874732
    Abstract: The present invention relates to thermally stable oral rotavirus vaccine formulations comprising one or more rotavirus reassortant or attenuated rotavirus strains, a pharmaceutically acceptable calcium salt, adipic acid, sucrose, and sodium phosphate, wherein each of the one or more rotavirus reassortant or attenuated rotavirus strain is stable for 7 days at 37° C., for 45 days at 25° C. and for 2 years or more at 2-8° C. The calcium containing formulations of the invention may further comprise one or more excipients which are present in an amount that is effective to optimize the calcium ions free in solution to stabilize the rotavirus particles. In embodiments of the invention, the formulation comprises a surfactant, such as polysorbate 80.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: December 29, 2020
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Robert K. Evans, Erica L. Strable, Lynne Isopi
  • Patent number: 10858400
    Abstract: Disclosed are immunogens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the immunogens and methods of producing the immunogens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the immunogen to the subject.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: December 8, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter Kwong, Barney Graham, Jason McLellan, Man Chen, Baoshan Zhang, Tongqing Zhou, Michael Gordon Joyce, Yongping Yang
  • Patent number: 10849970
    Abstract: The present invention relates, in general, to HIV-1 and, in particular, to broadly neutralizing HIV-1 antibodies, and to HIV-1 immunogens and to methods of using such immunogens to induce the production of broadly neutralizing HIV-1 antibodies in a subject (e.g., a human).
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: December 1, 2020
    Assignees: Duke University, Triad National Security, LLC, The Trustees of The University of Pennsylvania, Trustees of Boston University, The Government of The United States of America as Represented by the Secretary of the Department of Health and Human Services, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Barton F. Haynes, Hua-Xin Liao, Rebecca M. Lynch, Tongqing Zhou, Feng Gao, Scott Boyd, George M. Shaw, Beatrice H. Hahn, Thomas B. Kepler, Bette T. Korber, Peter Kwong, John R. Mascola
  • Patent number: 10844357
    Abstract: Highly antigenic yet safe vaccines against diseases caused by Paramyxoviridae viruses such as respiratory syncytial virus (RSV) are provided. The vaccines comprise attenuated Paramyxoviridae viruses with high antigenicity but which display impaired cell-to-cell transmission as a result of genetic manipulation of the gene encoding the matrix (M) protein. In the viruses, the M protein is absent or mutated to a less active form. Screening or assay systems and methods for evaluating the infectivity of mutant M proteins anf for identifying suitable M candidates for live-attenuated vaccine virus and VLP production, are also provided.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: November 24, 2020
    Assignee: The Board of Regents for Oklahoma State University
    Inventor: Antonius G. P. Oomens
  • Patent number: 10842862
    Abstract: The invention provides methods for using virus-like particle (VLP) vaccines containing a stabilized pre-fusion respiratory syncytial virus (RSV) F protein to stimulate RSV neutralizing antibodies in pre-immune subjects.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: November 24, 2020
    Assignee: University of Massachusetts
    Inventor: Trudy G Morrison
  • Patent number: 10815540
    Abstract: The present invention relates to a compound inducing activation of HLA-E-restricted CD8 T cells and/or NK cells in a human subject, and reducing HIV viral load, such as glatiramer acetate and glatiramer acetate related active substances and products, for use in the treatment of HIV infection. Macaques chronically infected by SIV have been treated with glatiramer acetate. One of the animals had already progressed to the stage of AIDS. We injected 18 mg of glatiramer acetate three times per week for only 2 weeks. Surprisingly, a strong impact on viral load was observed in response to the treatment. Viremia decreased by 1 log during glatiramer acetate treatment. Even more surprising was the fact that this decrease persisted after stopping the treatment reaching almost a 2 logs decrease in one animal. This is a major result as compared to cART as stopping cART leads to a rebound of the viral load within days.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: October 27, 2020
    Assignee: INSTITUT PASTEUR
    Inventors: Nicolas Huot, Beatrice Jacquelin, Michaela Muller-Trutwin